-+ 0.00%
-+ 0.00%
-+ 0.00%

Armata says AP-SA02 genetic diversity may boost killing of some Staph aureus isolates in clinical testing

PUBT·09/21/2026 11:02:11
Listen to the news
Armata says AP-SA02 genetic diversity may boost killing of some Staph aureus isolates in clinical testing
  • Armata Pharmaceuticals will present new AP-SA02 data at ISSSI 2026 on Sept. 21, 2026.
  • Results suggest controlled genetic diversity in the phage cocktail can improve killing of some Staphylococcus aureus clinical isolates.
  • Manufacturing is designed to keep this diversity consistent across clinical lots, positioning it as a deliberate product attribute.
  • Update supports plans to move AP-SA02 toward a Phase 3 superiority study in complicated S. aureus bacteremia.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Armata Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609210700PR_NEWS_USPR_____LA51176) on September 21, 2026, and is solely responsible for the information contained therein.